ACC CardiaCast: Which Patients Can Benefit from the Newly-Approved Cardiac Myosin Inhibitor Recently Approved for HCM

In this episode, Drs. Matt Martinez and Sara Saberi discuss the recent approval by the FDA of the cardiac myosin inhibitor Mavacamten for the treatment of hypertrophic cardiomyopathy, and what sorts of patients are best suited for this treatment.